Advanced stage non‐small cell lung cancer harboring oncogenic driver mutations such as epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, c‐Ros oncogene 1 (ROS1) gene rearrangements, and B‐rapidly accelerated fibrosarcoma (BRAF) gene mutations are treated with corresponding tyrosine kinase inhibitors.2 Here, ALK is linked to small cell lung carcinoma.